Breaking News Instant updates and real-time market news.

PFE

Pfizer

$35.79

-0.16 (-0.45%)

08:04
04/12/18
04/12
08:04
04/12/18
08:04

Pfizer initiates Phase 1b trial for DMD therapy candidate

Pfizer has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy, or DMD. The first boy received an infusion of the mini-dystrophin gene on March 22nd. Screening and enrollment of patients is expected to continue at up to four clinical research sites in the United States. Early data from this trial are expected in the first half of 2019, once all patients have been evaluated for one full year post-treatment. The multi-center, open-label, non-randomized, ascending dose study of a single intravenous infusion of PF-06939926 will enroll approximately 12 ambulatory boys aged 5 to 12 years with DMD. In addition to evaluating safety and tolerability, the study will evaluate measurements of dystrophin expression and distribution, as well as assessments of muscle strength, quality and function.

  • 24

    Apr

  • 25

    Apr

  • 08

    May

  • 05

    Jun

PFE Pfizer
$35.79

-0.16 (-0.45%)

04/05/18
LEHM
04/05/18
NO CHANGE
LEHM
Barclays upgrades Merck, downgrades Biogen and Pfizer in sector reassessment
Barclays analyst Geoff Meacham made some rating changes while reassessing the Biopharmaceutical sector. Biopharma sentiment has been negative since the start of 2018, despite a modest pick-up in deals and diminished rhetoric on drug pricing, Meacham tells investors in a research note titled "U.S. Biopharmaceuticals: Where to from here?" The analyst believes "more transformative" acquisitions, "clean" Phase 3 wins, and even a relatively strong Q1 earnings season could help "re-rate the sector" and get investors more engaged in the group. Ahead of the Q1 earnings season, Meacham upgraded Merck (MRK) to Overweight from Equal Weight and downgraded to Equal Weight from Overweight shares of Biogen (BIIB), Pfizer (PFE), Biohaven Pharmaceutical (BHVN) and Myovant Sciences (MYOV). The analyst also lowered his price target for Equal Weight-rated AbbVie (ABBV) to $102 from $120, for Equal Weight-rated Amgen (AMGN) to $180 from $180, for Overweight-rated Prothena (PRTA) to $50 from $70 and for Overweight-rated Incyte (INCY) to $135 from $165.
04/05/18
04/05/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Intel (INTC) downgraded to Hold from Buy at Stifel with analyst Kevin Cassidy citing the peaking server central processing unit cycle and valuation for the downgrade. 2. Johnson Controls (JCI) downgraded to Underperform from Sector Perform at RBC Capital with analyst Deane Dray citing the company's exposure to additional cash flow pressures in fiscal 2018, reduction in fiscal 2020 targets, and a market rotation toward "more defensive names." 3. Ryder (R) downgraded to Underweight from Neutral at JPMorgan with analyst Brian Ossenbeck saying he is making a "longer term call on 2019 expectations," which he believes are too high and embed "significant gains on residual values and used truck sales." 4. Ollie's Bargain Outlet (OLLI) downgraded to Neutral from Buy at BofA/Merrill with analyst Elizabeth Suzuki saying valuation is getting "richer," quarterly comps have been decelerating since 2015, and are now expected to be 1%-2% in 2018. 5. Biogen (BIIB), Pfizer (PFE), Biohaven (BHVN), and Myovant Sciences (MYOV) were downgraded to Equal Weight from Overweight at Barclays. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/12/18
SBSH
04/12/18
NO CHANGE
SBSH
Sell
Pfizer has no interest in acquiring Bristol-Myers right now, says Citi
Citi analyst Andrew Baum says Pfizer's (PFE) CEO made it clear to him that the company has no interest in acquiring Bristol-Myers Squibb (BMY) in the absence of transformational data or a de-rating in the shares. Pfizer has high conviction in its current pipeline and believes that the return on investment is considerably higher than high risk transformational deals, particularly in the immuno-oncology space, Baum tells investors in a research note. The analyst expects Pfizer will meaningfully increase its current share repurchase program from the current $5B-$6B per annum to offset the earnings dilution from higher anticipated R&D investment to monetize its current pipeline. Baum keeps a Sell rating on Pfizer and continues to prefer shares of Merck (MRK), Bristol and Eli Lilly (LLY) in the U.S. The analyst lowered his price target for Bristol shares to $70 from $78 with Pfizer backing away from a potential takeover. He keeps a Buy rating on the shares, however.
04/12/18
SBSH
04/12/18
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $78 at Citi
Citi analyst Andrew Baum lowered his price target for Bristol-Myers Squibb (BMY) to $70 after Pfizer (PFE) management made clear to him that they had no interest in acquiring Bristol without transformational data or a de-rating in the shares. The analyst removed the $8 per share risk adjusted M&A premium from his Bristol-Myers target price. He views his new price target as conservative, however, and keeps a Buy rating on the name.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
08/16/18
08/16
16:16
08/16/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATGE

Adtalem Global Education

$55.70

-0.3 (-0.54%)

16:15
08/16/18
08/16
16:15
08/16/18
16:15
Earnings
Adtalem Global Education sees FY19 revenue growth 3%-4% »

FY19 capital spending is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

AQMS

Aqua Metals

$2.42

0.04 (1.68%)

16:15
08/16/18
08/16
16:15
08/16/18
16:15
Hot Stocks
Aqua Metals CFO Francis Knuettel resigns »

On August 13 Francis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
08/16/18
08/16
16:15
08/16/18
16:15
General news
Breaking General news story  »

Week of 8/15 Fed Balance…

16:15
08/16/18
08/16
16:15
08/16/18
16:15
General news
Breaking General news story  »

Week of 8/6 Money Supply…

TSLA

Tesla

$335.46

-3.2 (-0.94%)

16:14
08/16/18
08/16
16:14
08/16/18
16:14
Periodicals
SEC presses Tesla directors for info on communications with Musk, WSJ says »

Federal regulators are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MRK

Merck

$68.85

1.49 (2.21%)

, ESALY

Eisai

$0.00

(0.00%)

16:14
08/16/18
08/16
16:14
08/16/18
16:14
Hot Stocks
Merck, Eisai announce FDA approval of LENVIMA capsules »

Eisai Inc. (ESALY) and…

MRK

Merck

$68.85

1.49 (2.21%)

ESALY

Eisai

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 24

    Aug

  • 10

    Sep

  • 12

    Sep

  • 03

    Oct

  • 23

    Oct

  • 29

    Oct

  • 16

    Feb

ATGE

Adtalem Global Education

$55.60

-0.4 (-0.71%)

16:13
08/16/18
08/16
16:13
08/16/18
16:13
Earnings
Breaking Earnings news story on Adtalem Global Education »

Adtalem Global Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

ARAY

Accuray

$3.50

0.05 (1.45%)

16:12
08/16/18
08/16
16:12
08/16/18
16:12
Hot Stocks
Accuray CFO Kevin Waters departing October 1, interim CFO appointed »

Accuray CFO Kevin Waters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

HDSN

Hudson Technologies

$1.76

-0.07 (-3.83%)

16:12
08/16/18
08/16
16:12
08/16/18
16:12
Hot Stocks
Hudson Technologies receives deficiency letter from Nasdaq »

Hudson Technologie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATGE

Adtalem Global Education

$55.65

-0.35 (-0.63%)

16:11
08/16/18
08/16
16:11
08/16/18
16:11
Earnings
Adtalem Global Education reports Q4 continuing operations EPS 86c, consensus 91c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

ARAY

Accuray

$3.50

0.05 (1.45%)

16:11
08/16/18
08/16
16:11
08/16/18
16:11
Earnings
Accuray sees FY19 revenue $415M-$425M, consensus $398.38M »

Sees adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

AMAT

Applied Materials

$47.19

-0.3 (-0.63%)

16:11
08/16/18
08/16
16:11
08/16/18
16:11
Hot Stocks
Breaking Hot Stocks news story on Applied Materials »

Applied Materials reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

ATAI

ATA Inc.

$6.80

0.06 (0.89%)

16:09
08/16/18
08/16
16:09
08/16/18
16:09
Hot Stocks
ATA Inc. to acquire Beijing Biztour »

ATA Inc announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAT

Mattel

$15.17

-0.11 (-0.72%)

16:08
08/16/18
08/16
16:08
08/16/18
16:08
Hot Stocks
Mattel names Steve Totzke as Chief Commercial Officer »

Mattel announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$47.25

-0.24 (-0.51%)

16:08
08/16/18
08/16
16:08
08/16/18
16:08
Hot Stocks
Breaking Hot Stocks news story on Applied Materials »

Applied Materials down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

JWN

Nordstrom

$52.11

0.25 (0.48%)

16:08
08/16/18
08/16
16:08
08/16/18
16:08
Earnings
Nordstrom raises FY18 EPS view to $3.50-$3.65 from $3.35-$3.55 »

Consensus $3.46. Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

PFNX

Pfenex

$4.77

0.07 (1.49%)

16:08
08/16/18
08/16
16:08
08/16/18
16:08
Hot Stocks
Pfenex CMO Dr. Hubert Chen resigns »

Pfenex announced that Dr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARAY

Accuray

$3.50

0.05 (1.45%)

16:07
08/16/18
08/16
16:07
08/16/18
16:07
Earnings
Accuray reports Q4 EPS (1c), consensus (2c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

ICFI

ICF International

$80.65

1.15 (1.45%)

16:07
08/16/18
08/16
16:07
08/16/18
16:07
Hot Stocks
ICF International awarded $20M task order from DHIS »

ICF was recently awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZOES

Zoe's Kitchen

$9.48

(0.00%)

16:07
08/16/18
08/16
16:07
08/16/18
16:07
Hot Stocks
Zoe's Kitchen postpones earnings release, conference call until August 17 »

Zoe's Kitchen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

JWN

Nordstrom

$52.13

0.27 (0.52%)

16:06
08/16/18
08/16
16:06
08/16/18
16:06
Earnings
Nordstrom reports Q2 EPS 95c, consensus 84c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

AMAT

Applied Materials

$47.26

-0.23 (-0.48%)

16:06
08/16/18
08/16
16:06
08/16/18
16:06
Earnings
Applied Materials sees FY18 EPS $4.41-$4.49, consensus $4.59 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

EDIT

Editas Medicine

$29.80

0.7 (2.41%)

16:05
08/16/18
08/16
16:05
08/16/18
16:05
Hot Stocks
Editas Medicine announces completion of recombinant DNA committee registration »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

ESRX

Express Scripts

$87.21

0.52 (0.60%)

, CI

Cigna

$187.93

2.48 (1.34%)

16:05
08/16/18
08/16
16:05
08/16/18
16:05
Hot Stocks
Express Scripts urges stockholders to vote in favor of merger with Cigna »

Express Scripts (ESRX)…

ESRX

Express Scripts

$87.21

0.52 (0.60%)

CI

Cigna

$187.93

2.48 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 24

    Aug

  • 12

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.